|
Described herein are methods that can be used for diagnosis and
prognosis of breast cancer. Also described herein are methods that
can be used to screen candidate bioactive agents for the ability
to modulate breast cancer. Additionally, methods and molecular targets
(genes and their products) for therapeutic intervention in breast
cancer are described.
The present invention provides a new method of detecting, diagnosing,
monitoring, staging, prognosticating, imaging and treating breast
cancer.
The present invention provides a new method for detecting, diagnosing,
monitoring, staging, and prognosticating breast cancer.
Compounds of the class of 4-oxo-butenoic acid derivatives are disclosed
along with the surprising use property of these compounds as a anti-tumor
agents in humans against breast carcinoma, which include: 2-(N'-Fluoren-9-ylidene-hydrazino)5,5-dimethyl-4-oxo-hex-2-enoic
acid methyl ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-(4-methyl-benzoyl)-5-oxo-2,5-dihyd
ro-1H-pyrrole-2-carboxylic acid methyl ester (1F-07), 4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric
acid (3F-10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric
acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafluoro-4-methoxy-phenyl)-but-2-enoic
acid (3F-15), and 4,4-Dihydroxy-5-(4-methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one
(3F-16) as well as some novel derivatives of these compounds claimed
(see Table 2). The invention also encompasses a class of the compounds
with the novel property of anti-tumor activity against human breast
cancer, which includes the following compounds 4-(4-Ethoxy-phenyl)-2-(N'-fluoren-9-ylidene-hydrazino)-2-hydroxy-4-oxo-but
yric acid methyl ester (OF-13); 2-{N'-[1-(4-Chloro-phenyl)-ethylidene]-hydrazino}-4-oxo-4-phenyl-but-2-eno
ic acid methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)-4-oxo-4-phenyl-but-2-enoic
acid methyl ester (1F-04); and 4-Chloro-4-(4-ethoxy-phenyl)-2-(fluoren-9-ylidene-hydrazono)-but-3-enoic
acid methyl ester (3F-19).
|